TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...

A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy. Complement Therapeutics (CTx) is a Germany-based preclinical stage biotechnology company focusing on the R ...

Arrowhead Pharmaceuticals Inc. has filed an application in New Zealand seeking clearance to initiate a phase I/IIa trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

A preclinical biotechnology company, spun out of The University of Manchester, has announced the completion of a €72 million finance deal to develop the treatment of a leading cause of blindness. The ...